RT Journal Article
SR Electronic
T1 The Mexican dataset of a repetitive transcranial magnetic stimulation clinical trial on cocaine use disorder patients: SUDMEX TMS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.21.23291661
DO 10.1101/2023.06.21.23291661
A1 Angeles-Valdez, Diego
A1 Rasgado-Toledo, Jalil
A1 Villicaña, Viviana
A1 Davalos-Guzman, Alan
A1 Almanza, Cristina
A1 Fajardo-Valdez, Alfonso
A1 Alcala-Lozano, Ruth
A1 Garza-Villarreal, Eduardo A.
YR 2023
UL http://medrxiv.org/content/early/2023/06/28/2023.06.21.23291661.abstract
AB Cocaine use disorder (CUD) is a worldwide problem with severe health and socio-economic consequences, which results in behavioral, cognitive, and neurobiological disturbances. Consensus on treatments are still under discussion, however, repetitive transcranial magnetic stimulation (rTMS) has been proposed as a promising treatment for medication-resistant disorders, including substance use disorders. Here, we describe the Mexican dataset of an rTMS clinical trial in patients with CUD (SUDMEX-TMS), a longitudinal dataset of 54 CUD participants (8 female) with five timepoints: baseline (T0), two weeks (T1), three months (T2), six months (T3) follow-up, and twelve months (T4) follow-up. Clinical rTMS treatment consisted of a double-blinded randomized clinical trial (n = 24 sham/30 active) for 2 weeks and open label afterwards, and includes demographic, clinical, and cognitive measures, as well as magnetic resonance imaging (MRI) acquisition in all timepoints: 1) structural (T1-weighted), 2) functional (resting state fMRI), and 3) multishell high-angular resolution diffusion-weighted (DWI-HARDI) sequences. The present dataset could be used to examine the impact of rTMS on CUD participants in clinical, cognitive, and multimodal MRI metrics in a longitudinal design.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02986438Funding StatementThis study was supported by public funds CONACYT FOSISS No. 0260971 and CONACYT No. 253072Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the Instituto Nacional de Psiquiatria - Ramon de la Fuente Muniz (CEI/C/070/2016)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors, and all data produced are available online at https://zenodo.org/record/7126853